BOC Sciencesís CDMO Helps Overcome the Last Hurdle of ADC R&D
The past decade has been a decade of accumulation and harvest of antibody-conjugated drugs (ADC). Breakthroughs have been made in the bottleneck of ADC research, the door to success has been opened, and more and more antibody-conjugated drugs have entered the research and development pipeline. However, the research team of ADC drugs is still facing huge R&D and production challenges. Recently, BOC Sciences announced that it will provide one-stop CDMO services to help overcome the challenges in the R&D and production of ADC drugs.
In the past, ADC R&D researchers needed to collaborate with at least 4 CDMOs on mAb, payload, linker, and conjugation methods respectively to promote ADC to clinical trials and the market. Moreover, if the partners are located in different countries and regions, ADC R&D researchers will face the challenges of a complex global supply chain.
With the continuous advancement of ADC drug clinical research and the rising demand for commercialization, more and more researchers hope that CDMO companies can use an "end-to-end" model to simplify the CMC process and global supply chain management of ADC drugs from R&D to marketing.
Advantages of BOC Sciencesís ADC platform In recent years, BOC Sciences has increased its investment and created an end-to-end, one-stop service platform for the R&D and production of ADC drug to rapidly advance the partnersí R&D.
BOC Sciences can not only provide MMAE/MMAF, DM1/DM4, Calicheamicin, Duocarmycin, Doxorubicin, SN-38, PBD, and other commonly used ADC payloads, but also develop and produce a variety of new payloads, and cleavable and non-cleavable conjugates.
Through efficient collaboration between the research and development, production, and analysis teams at the same base, BOC Sciences has greatly shortened the process of ADC drug development and production. Up to now, all laboratories have complied with the most stringent EHS standards in the industry and have passed many inspections by major global regulatory agencies.